EHS
EHS

Liver graft injury caused by de novo donor-specific HLA antibodies in pediatric liver transplant recipients with low, moderate, and high immunologic risk


    • O’Leary J.G.
    • Kaneku H.
    • Jennings L.W.
    • et al.

    Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation.

    Liver Transplant. 2013; 19 (973–0)https://doi.org/10.1002/lt.23687

    • Tokodai K.
    • Miyagi S.
    • Nakanishi C.
    • et al.

    Association of post-transplant donor-specific HLA antibody with liver graft fibrosis during long-term follow-up after pediatric liver transplantation.

    Pediatr Transplant. 2018; 22e13169https://doi.org/10.1111/petr.13169

    • Terasaki P.I.

    Humoral theory of transplantation.

    Am J Transplant. 2003; 3: 665-673https://doi.org/10.1034/j.1600-6143.2003.00135.x

    • Musat A.I.
    • Agni R.M.
    • Wai P.Y.
    • et al.

    The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation.

    Am J Transplant. 2011; 11: 500-510https://doi.org/10.1111/j.1600-6143.2010.03414.x

    • O’Leary J.G.
    • Kaneku H.
    • Susskind B.M.
    • et al.

    High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant.

    Am J Transplant. 2011; 11: 1868-1876https://doi.org/10.1111/j.1600-6143.2011.03593.x

    • Wozniak L.J.
    • Hickey M.J.
    • Venick R.S.
    • et al.

    Donor-specific HLA antibodies are associated with late allograft dysfunction after pediatric liver transplantation.

    Transplantation. 2015; 99: 1416-1422https://doi.org/10.1097/TP.0000000000000796

    • Kaneku H.
    • O’Leary J.G.
    • Banuelos N.
    • et al.

    De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients.

    Am J Transplant. 2013; 13: 1541-1548https://doi.org/10.1002/ajt.12212

    • O’Leary J.G.
    • Kaneku H.
    • Susskind B.M.
    • et al.

    High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection Postliver transplant.

    Am J Transplant. 2011; 11: 1868-1876https://doi.org/10.1111/j.1600-6143.2011.03593.x

    • Muro M.
    • López-Alvarez M.R.
    • Campillo J.A.
    • et al.

    Influence of human leukocyte antigen mismatching on rejection development and allograft survival in liver transplantation: is the relevance of HLA-A locus matching being underestimated?.

    Transpl Immunol. 2012; 26: 88-93https://doi.org/10.1016/j.trim.2011.11.006

    • Kaczmarek I.
    • Deutsch M.A.
    • Kauke T.
    • et al.

    Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant.

    Exp Clin Transplant. 2008; 63: 229-235

    • Smith J.D.
    • Banner N.R.
    • Hamour I.M.
    • et al.

    De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival.

    Am J Transplant. 2011; 11: 312-319https://doi.org/10.1111/j.1600-6143.2010.03383.x

    • Taner T.
    • Gandhi M.J.
    • Sanderson S.O.
    • et al.

    Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year.

    Am J Transplant. 2012; 12: 1504-1510https://doi.org/10.1111/j.1600-6143.2012.03995.x

    • Starzl T.E.
    • Demetris A.J.
    • Todo S.
    • et al.

    Evidence for hyperacute rejection of human liver grafts: the case of the canary kidneys.

    Clin Transplant. 1989; 3: 37-45

    • Kozlowski T.
    • Rubinas T.
    • Nickeleit V.
    • et al.

    Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies.

    Liver Transplant. 2011; 17: 357-368https://doi.org/10.1002/lt.22233

    • Paterno F.
    • Shiller M.
    • Tillery G.
    • et al.

    Bortezomib for acute antibody-mediated rejection in liver transplantation.

    Am J Transplant. 2012; 12: 2526-2531https://doi.org/10.1111/j.1600-6143.2012.04126.x

    • Musat A.I.
    • Pigott C.M.
    • Ellis T.M.
    • et al.

    Pretransplant donor-specific anti-HLA antibodies as predictors of early allograft rejection in ABO-compatible liver transplantation.

    Liver Transplant. 2013; 19: 1132-1141https://doi.org/10.1002/lt.23707

    • Musat A.I.
    • Agni R.M.
    • Wai P.Y.
    • et al.

    The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation.

    Am J Transplant. 2011; 11 (10. 1111/j.1600-6143.2010.03414.x): 500-510

    • Demetris A.J.
    • Markus B.H.
    • Burnham J.
    • et al.

    Antibody deposition in liver allografts with chronic rejection.

    Transplant Proc. 1987; 19: 121-125

    • Del Bello A.
    • Congy-Jolivet N.
    • Muscari F.
    • et al.

    Prevalence, incidence and risk factors for donor specific anti-HLA antibodies in maintenance liver transplant patients.

    Am J Transplant. 2014; 14: 867-875https://doi.org/10.1111/ajt.12651

    • Miyagawa-Hayashino A.
    • Yoshizawa A.
    • Uchida Y.
    • et al.

    Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts.

    Liver Transplant. 2012; 18: 1333-1342https://doi.org/10.1002/lt.23534

    • Wozniak L.J.
    • Hickey M.J.
    • Venick R.S.
    • et al.

    Donor-specific HLA antibodies are associated with late allograft dysfunction after pediatric liver transplantation.

    Transplantation. 2015; 99: 1416-1422https://doi.org/10.1097/TP.0000000000000796

    • Demetris A.J.
    • Bellamy C.
    • Hübscher S.G.
    • et al.

    Comprehensive update of the Banff working group on liver allograft pathology:introduction of antibody-mediated rejection.

    Am J Tranplant. 2016; (2016): 1-20https://doi.org/10.1111/ajt.13909

    • Wozniak L.J.
    • Hickey M.J.
    • Venick R.S.
    • et al.

    Donor-specific HLA antibodies are associated with late allograft dysfunction after pediatric liver transplantation.

    Transplantation. 2015; 99: 1416-1422https://doi.org/10.1097/TP.0000000000000796

    • Grabhorn E.
    • Binder T.M.
    • Obrecht D.
    • et al.

    Long-term clinical relevance of de novo donor-specific antibodies after pediatric liver transplantation.

    Transplantation. 2015; 99: 1876-1881https://doi.org/10.1097/TP.0000000000000638

    • Wozniak L.J.
    • Naini B.V.
    • Hickey M.J.
    • et al.

    Acute antibody-mediated rejection in ABO-compatible pediatric liver transplant recipients: case series and review of the literature.

    Pediatr Transplant. 2017; 21: 1-13https://doi.org/10.1111/petr.12791

    • Miyawa-Hayashino A.
    • Yoshizawa A.
    • Uchida Y.
    • et al.

    Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts.

    Liver Transplant. 2012; 18: 1333-1342https://doi.org/10.1002/lt.23534

    • Hubscher S.G.
    • Adams D.H.
    • Elias E.

    Changes in the expression of major histocompatibility complex class II antigens in liver allograft rejection.

    J Pathol. 1990; 162: 165-171https://doi.org/10.1002/path.1711620210

    • Steinhoff G.
    • Wonigeit K.
    • Pichlmayr R.

    Analysis of sequential changes in major histocompatibility complex expression in human liver grafts after transplantation.

    Transplantation. 1988; 45: 394-401https://doi.org/10.1097/00007890-198802000-00030

    • Steinhoff G.

    Major histocompatibility complex antigens in human liver transplants.

    J Hepatol. 1990; 11: 9-15https://doi.org/10.1016/0168-8278(90)90264-r

    • Wiebe C.
    • Gibson I.W.
    • Blydt-Hansen T.D.
    • et al.

    Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant.

    Am J Transplant. 2012; 12: 1157-1167https://doi.org/10.1111/j.1600-6143.2012.04013.x

    • Everly M.J.
    • Rebelatto L.M.
    • Haisch C.E.
    • et al.

    Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.

    Transplantation. 2013; 95: 410-417https://doi.org/10.1097/TP.0b013e31827d62e3

    • Schluckebier D.
    • Cousin V.L.
    • Petit L.M.
    • et al.

    Preformed and de novo DSA are associated with T-cell-mediated rejection in pediatric liver transplant recipients requiring clinically indicated liver biopsy.

    Pediatr Transplant. 2020; 24e13611https://doi.org/10.1111/petr.13611

    • Miyagawa-Hayashino A.
    • Yoshizawa A.
    • Uchida Y.
    • et al.

    Progressive graft fibrosis and donor-specific HLA antibodies in pediatric late liver allografts.

    Liver Transplant. 2012; 18: 1333-1342https://doi.org/10.1002/lt.23534

    • Ueno T.
    • Zenitani M.
    • Yamanaka H.
    • et al.

    Impact of donor-specific antibodies on graft fibrosis after pediatric living donor liver transplantation for biliary atresia.

    Transplant Proc. 2016; 48: 1095-1099https://doi.org/10.1016/j.transproceed.2016.02.011

    • Tokodai K.
    • Miyagi S.
    • Nakanishi C.
    • et al.

    Association of post-transplant donor-specific HLA antibody with liver graft fibrosis during long-term follow-up after pediatric liver transplantation.

    Pediatr Transplant. 2018; 22e13169https://doi.org/10.1111/petr.13169

    • Ohe H.
    • Uchida Y.
    • Yoshizawa A.
    • et al.

    Association of anti-human leukocyte antigen and anti-angiotensin II type 1 receptor antibodies with liver allograft fibrosis afterimmunosuppression withdrawal.

    Transplantation. 2014; 98 (10. 1097/TP.0000000000000185): 1105-1111

    • Markiewicz-Kijewska M.
    • Kalicinski P.
    • Kluge P.
    • et al.

    Immunological factors and liver fibrosis in pediatric liver transplant recipients.

    Ann Transplant. 2015; 20: 279-284https://doi.org/10.12659/AOT.892544



  • Source link

    EHS
    Back to top button